Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study

We present results of the prespecified interim futility analysis.

Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Atsuo Takashima, Pilar Garc ía-Alfonso, Raimundo Manneh, Ali Ayberk Beşen, Yong Sang Hong, Pieter-Jan Cuyle, Patricio Yanez, Matthew Burge, Takayuki Yoshino, Tae Won Kim, Karen Cui, Chenxiang Li, Rishi Jain, David Adelberg, Julien Taieb Tags: Original Research Source Type: research